Zwangsstörungen

Kernaussagen

• Die Zwangsstörung ist eine schwere, meist chronische psychische Erkrankung, die häufig vor anderen Personen, insbesondere auch vor Ärzten und Psychotherapeuten, verheimlicht wird.

• Zwangsstörungen weisen eine hohe Komorbidität mit anderen psychischen Erkrankungen auf, insbesondere mit depressiven Störungen, Angststörungen, Persönlichkeitsstörungen und Essstörungen.

• An effektiven Behandlungsstrategien steht heute die kognitive Verhaltenstherapie mit Reizkonfrontation (Exposition) und Reaktionsmanagement sowie selektive Serotonin-Wiederaufnahmehemmer zur Verfügung. Die Kombination beider Verfahren kann zu Responderraten von 80 bis 90 % der Patienten führen. Bei Therapieresistenz ist die Wirksamkeit atypischer Neuroleptika erwiesen.

• Behandlungserfolg bzw. Response bedeutet bei Zwangsstörungen meist eine deutliche Symptomreduktion, äußerst selten jedoch eine Remission.

• Die Versorgungssituation für Patienten, die an Zwangsstörungen erkrankt sind, ist noch sehr unzureichend. Bei vielen Patienten werden unwirksame Fehlbehandlungen durchgeführt, bevor spezifische, evidenzbasierte Therapien zur Anwendung kommen.

Publikationsverlauf

Publikationsdatum:
16. April 2007 (online)

• Literatur

• Kessler R, McGonagle K, Zhao S. Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.. Arch Gen Psych 1994; 51: 8-19
• Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder.. Arch Gen Psychiat 1999; 56: 121-127
• Stengler-Wenzke K, Beck M, Holzinger A, Angermeyer MC. Stigmatisierungserfahrungen von Patienten mit Zwangserkrankungen.. Fortschritte der Neurologie - Psychiatrie 2004; 72: 7-13
• Winkelmann G, Rasche H, Hohagen F. Zwangsstörungen: Komorbidität und Implikationen für die Behandlung.. Praxis der Rehabilitation und Verhaltenstherapie 1994; 25: 32-40
• Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder.. Psychiatric Clinics of North America 1992; 15: 743-758
• Nestadt G, Samuels J, Riddle MA. et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study.. Psychological Medicine 2001; 31: 481-7
• Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.. Arch Gen Psychiatry 1998; 45: 977-86
• Poyurovsky M, Weizmann A, Weizmann R. Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment.. CNS Drugs 2004; 18: 989-1010
• Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics.. J Clin Psychiatry 1998; 59: 45-49
• Mancebo MC, Eisen JL, Grant JE, Rasmussen SA. Obsessive compulsive personality disorder and obsessive compulsive disorder: clinical characteristics, diagnostic difficulties, and treatment.. Annales of Clinical Psychiatry 2005; 17: 197-204
• Dale RC, Heyman I, Giovannoni G, Church AW. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder.. Br J Psychiatry 2005; 187: 314-319
• Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder.. Psychiatry Res 2004; 15: 69-79
• Rauch SL. Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders.. Neurosurg Clin N Am 2003; 14: 213-23
• Rauch SL, Jenike MA, Alpert NM. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography.. Arch Gen Psychiatry 1994; 51: 62-70
• Billet EA, Richter MA, Kennedy JL. Genetics of obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA Obsessive-Compulsive Disorder. Theory, research, and treatment.. New York, London, The Guilford Press: 1998: 181-206
• Kuelz AK, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review.. Biological Psychology 2004; 65: 185-236
• Kuelz AK, Riemann D, Halsband U. et al. Neuropsychological impairment in OCD - improvement over the course of cognitive behavioral treatment.. Journal of Clinical and Experimental Neuropsychology 2006; 28: 1-15
• Salkovskis WM, Warwick HM. Cognitive therapy of obsessive - compulsive disorder. In: Paris C, Blackburn IM, Perris H Cognitive Psychotherapy - Theory and Practice.. Berlin,Springer: 1988
• Abramowitz JS. The Psychological Treatment of Obsessive Compulsive Disorder.. Can J Psychiatry 2006; 51: 407-416
• Neziroglu F, Henricksen J, Yaryura-Tobias JA. Psychotherapy of obsessive-compulsive disorder and spectrum: established facts and advances, 1995 - 2005.. Psychiatric Clinics of North America 2006; 29: 585-604
• Mataix-Cols D, Marks IM. Self-help with minimal therapist contact for obsessive-compulsive disorder: a review.. European Psychiatry 2006; 21: 75-80
• Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Räuchle H, Hohagen F. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up.. European Archives of Psychiatry & Clinical Neuroscience Feb 2005; 255: 48-50
• Rufer M, Hand I, Alsleben H. et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.. Eur Arch Psych Clin Neurosci 2005; 255 (2): 121-128
• Blier P, Habib R, Flament MF. Pharmacotherapies in the Management of Obsessive-Compulsive Disorder.. Can J Psychiatry 2006; 51: 417-430
• Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.. Psychiatric Clinics of North America 2006; 29: 553-84
• Bergqvist PB, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.. Biological Psychiatry 1999; 45: 164-74
• Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.. J Clin Psychopharmacol 2002; 22: 309-17
• Denys D, Megen HJ van, Wee N van der  , Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.. Journal of Clinical Psychiatry 2004; 65: 37-43
• Foa EB, Liebowitz MR, Kozak MJ. et al. Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramin, and their Combination in the Treatment of Obsessive-Compulsive Disorder.. Am J Psychiatry 2005; 162: 151-161
• Hohagen F, Winkelmann G, Rasche RH. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.. Br J Psychiatry 1998; Suppl 35: 71-78
• Geller DA, Biederman J, Stewart SE. et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.. Am J Psychiatry 2003; 160: 1919-1928
• Hoehn-Saric SR, Ninan P, Black DW. et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.. Arch Gen Psychiatry 2000; 57: 76-82
• Greenberg BD, Malone DA, Friehs GM. et al. Three-Year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.. Neuropsychopharmacology 2006; 31: 2384-2393
• March JS, Frances A, Kahn DA, Carpenter D. The Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder.. J Clin Psychiatry 1997; 58 (suppl 4): 0
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders.. World J Biol Psychiatry 2002; 3 (4): 171-199